Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patisiran versus placebo in transthyretin amyloidosis with cardiomyopathy
NL-OMON58738Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Feb 2021
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloidosis (ATTR) comparing Patisiran with Placebo (2 arms). Primary endpoint: Change from baseline in 6-minute walk test. Started Feb 2021; status: completed.
02
Drugs
patisiran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NL-OMON58738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58738.